Chronic migraine and Botulinum Toxin Type A: Where do paths cross?

Martinelli, Daniele; Arceri, Sebastiano; Tronconi, L; Tassorelli, Cristina

doi:10.1016/j.toxicon.2020.02.017

Cited by 18 publications

(14 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At baseline, the median (Q1-Q3) number of migraine days was 12 (10)(11)(12)(13)(14)(15). The number of median migraine days reduced to 8 (6-9) at 6 months (p < 0.001) and to 5 (4-7) at 12 months (p < 0.001) ( Table 1).…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A

et al. 2020

View full text Add to dashboard Cite

The present study aims to describe the efficacy and safety of onabotulinum toxin A (BonT-A) with evaluation of treatment satisfaction and impact on quality of life in chronic migraine (CM) patients in real life. Methods: This study was conducted in CM patients who were treated with BoNT-A with 12 months of follow-up. Data about outcome, adverse events, and patients' pre-and post-treatment status including health-related quality of life data were analyzed. Health-related quality of life scores were measured at baseline and months 6 and 12 after the beginning of BoNT-A administration. Results: Of 42 enrolled patients, 30 were included in the analysis. At 12 months, all patients showed a reduction in number of headaches and analgesic use per month and none reported adverse events. After BoNT-A supplementation, health-related quality-of-life scores improved significantly. There was a direct association between healthrelated quality of life with reduction of headache days at the end of study. Conclusion: This study confirms that BoNT-A treatment is effective on CM and improves the functional well-being and quality of life of patients.

show abstract

Section: Resultsmentioning

confidence: 98%

“…CM is a highly prevalent problem affecting 1.4–2.2% of the population as determined by studies in many parts of the world [12, 13]. The disease may have long-term psychosocial effects that drastically alter daily activities.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At the pre-synaptic space there are vesicles, nearby the terminal nerve [27], creating a pool filled by neurotransmitters, whose contents could be released in the synap-tic junction to activate a signal transmission process after exocytosis. This last process is realized only after assemblation of syntaxin 1A and SNAP-25 (synaptosomalassociated protein), on the plasma membrane and synaptobrevin 2 (VAMP2) on the vesicular membrane to bridge the two opposite membranes in the 'fusion' step [20,28]. The fusion complex VAMP/synaptobrevin/SNAP-25 and syntaxin, is called SNARE complex [29].…”

Section: Mechanism Of Action Of Onabont-amentioning

confidence: 99%

Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions

Raciti¹,

Raciti²,

Militi³

et al. 2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Chronic migraine belongs to the "chronic long-duration headaches", and it is associated to high burden and significant economic impact. Treatment for both episodic (EM) and chronic migraine (CM) is based on the management of acute attacks and their prevention. For moderate/severe attacks, pharmacological therapies are triptans, dihydroergotamine nasal sprays or injections or neuroleptics, non-steroidal anti-inflammatory drugs, and corticosteroids. Chronic migraine belongs to the "chronic long-duration headaches", and it is associated to high burden and significant economic impact. Treatment for both episodic (EM) and chronic migraine (CM) is based on the management of acute attacks and their prevention. For moderate/severe attacks, pharmacological therapies are triptans, dihydroergotamine nasal sprays or injections or neuroleptics, non-steroidal anti-inflammatory drugs, and corticosteroids. The pathophysiology of CM is characterized by an abnormal activation of the trigemino-vascular system in the meninges causing a neurogenic inflammation, which explains the use of anti-inflammatory during attacks. It seems that the objective of the preventive therapy with the botulin toxin OnaBoNT-A consists in interrupting the release of CGRP and other neuropeptides as well as the activation of C-fiber nociceptor and of the nearby A-delta fibers. The protocol for migraine treatment with OnaBoNT-A injections consists of 31-39 pericranial injection sites involving seven muscle groups bilaterally in specific areas of the head and neck, with a total dose of between 155 and 195 units, every three months. The severe adverse events reported with high doses of botulin toxin for spasticity, have not been reported for CM treated with OnabotA at the labeled dose. The established improvement with onabotulinumtoxinA treatment in CM patients had a positive impact not only in reduction monthly headache days but also in improving quality of life, with reduction in both healthcare resource utilisation (HRU) and work impairment. Aim of this review was to give an overview on the use of BoNT-A in patients with CM, giving practical advices on the clinical indications.

show abstract

“…Pain. The only approved indication for BoNT is chronic migraine, where it acts by interfering with peripheral and possibly central sensitization, and its main role is the block of vasoactive peptides release from trigemino-vascular endings [ 42 ]. BoNT has been used successfully in neuropathic pain, mainly of peripheral origin (postherpetic neuralgia, diabetic neuropathy) [ 43 ].…”

Section: Therapeutic Use For Botulinum Neurotoxinsmentioning

confidence: 99%

Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury

Palazón-García

Benavente-Valdepeñas

2021

IJMS

View full text Add to dashboard Cite

Botulism has been known for about three centuries, and since its discovery, botulinum toxin has been considered one of the most powerful toxins. However, throughout the 20th century, several medical applications have been discovered, among which the treatment of spasticity stands out. Botulinum toxin is the only pharmacological treatment recommended for spasticity of strokes and cerebral palsy. Although its use as an adjuvant treatment against spasticity in spinal cord injuries is not even approved, botulinum toxin is being used against such injuries. This article describes the advances that have been made throughout history leading to the therapeutic use of botulinum toxin and, in particular, its application to the treatment of spasticity in spinal cord injury.

show abstract

Chronic migraine and Botulinum Toxin Type A: Where do paths cross?

Cited by 18 publications

References 82 publications

Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A

Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A

Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions

Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury

Contact Info

Product

Resources

About